Biosciences sales rise 8% at CSL
This article was originally published in Clinica
Executive Summary
Australian company CSL's biosciences division has reported sales of Aus$12.5 million ($9.6 million) for fiscal 1995 (ended June 30th). The 8% growth in sales of core products - blood grouping reagents, infectious disease diagnostics and products for research laboratories - was able partly to offset the reduction in total revenue brought about by the transfer of the division's international cell culture business to JRH Biosciences which followed the acquisition of JRH by CSL in September 1994.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.